Company NexImmune, Inc.

Equities

NEXI

US65344D2080

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 03:59:53 2024-06-14 pm EDT			5-day change	1st Jan Change
2.95 ^USD	+1.72%		-1.67%	+32.88%

May. 20	NexImmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ

NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the bodyâs own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.

Number of employees: 6

Managers	Title	Age	Since
Kristi Jones CEO	Chief Executive Officer	60	17-05-31
Mathias Oelke FOU	Founder	56	11-06-06
Tonya Catterton CMP	Compliance Officer	-	-
Chad Rubin IRC	Investor Relations Contact	-	21-04-20
Karen Haslbeck HRO	Human Resources Officer	-	19-08-31
Matthew Schiller PRN	Corporate Officer/Principal	-	21-07-13

Members of the board	Title	Age	Since
Sol Barer CHM	Chairman	76	19-12-15
Zheng Bin Yao BRD	Director/Board Member	58	16-12-31
Alan Roemer BRD	Director/Board Member	54	17-01-31
Grant Verstandig BRD	Director/Board Member	34	21-01-18
Tim Bertram BRD	Director/Board Member	68	16-12-31
Paul D'Angio BRD	Director/Board Member	65	16-12-31
Kristi Jones CEO	Chief Executive Officer	60	17-05-31
Leena Gandhi BRD	Director/Board Member	53	22-04-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,371,051	1,070,168 ( 78.05 %)	0	78.05 %

Name	Equities	%	Valuation
Sol Barer 6.470 %	88,712	6.470 %	271 459 $
Joshua Barer 5.498 %	75,383	5.498 %	230 672 $
Sabby Management LLC 4.365 %	59,851	4.365 %	183 144 $
Grant Verstandig 3.225 %	44,219	3.225 %	135 310 $
Slate Path Capital LP 2.699 %	36,999	2.699 %	113 217 $
EPIQ Capital Group LLC 1.140 %	15,624	1.140 %	47 809 $
PNC Financial Services Group, Inc. (13F Subfiler) 0.9219 %	12,640	0.9219 %	38 678 $
Vanguard Group, Inc. (Subfiler) 0.8760 %	12,010	0.8760 %	36 751 $
Raymond James & Associates, Inc. 0.7880 %	10,804	0.7880 %	33 060 $
Comerica Bank (Dallas, Texas) 0.2375 %	3,256	0.2375 %	9 963 $

NexImmune, Inc.

9119 Gaither Road

20877, Gaithersburg

+301 825 9810

http://www.neximmune.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NEXIMMUNE, INC.	+32.88%	4.04M
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
BIONTECH SE	-12.75%	22.22B
ARGENX SE	+5.07%	22.94B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-14.97%	16.88B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs